Modern Vaccines with DIVA Capability: An Overview
DOI:
https://doi.org/10.37591/rrjoi.v5i1.1245Abstract
DIVA vaccines are designed to achieve twin-goals of the immunological protection of the host and the immunological differentiation of the infected from the vaccinated animals (DIVA) with a companion immunodiagnostic test. The DIVA strategy is used in countries that follow the vaccination path for elimination of an infectious disease and ultimately to achieve the disease-free status for international trade. This strategy has also been advocated for and adopted in the disease-free countries in emergencies to contain outbreaks and to regain the disease-free status. Essential steps in development of a novel DIVA strategy are: (i) selection of the appropriate marker gene/antigen for the vaccine, (ii) the construction of the marker vaccine, and (iii) development and validation of the marker antigen-based immuno-differentiation test. The first DIVA vaccines (pseudorabies, infectious bovine rhinotracheitis and classical swine fever virus) were constructed during 1980s–1990s by deleting a non-essential gene of each virus that encoded for the ‘marker’ antigen. Detection of anti-marker antibodies in the infected animals was achieved by an immunological test. Other approaches in DIVA vaccinology have been developed since then, most of them employing rDNA techniques. Live attenuated or killed whole organisms, chimeric and live expression vectors and subunit constructs have been licensed as DIVA vaccines for various infectious diseases. In fact, all non-whole organism vaccines produced by rDNA techniques and synthetic chemistry procedures possess inherent DIVA capability. The biomarkers-based DIVA approaches are also conceived for future. An overview of DIVA vaccinology and diagnostics is presented.
Keywords: DIVA vaccinology, marker antigens, DIVA diagnostics, rDNA-based vaccines
Cite this Article:
A. Singh. Modern Vaccines with DIVA Capability: An Overview. Research and Reviews: Journal of Immunology (RRJoI). 2015; 5(1): 1–12p.
Downloads
Published
Issue
Section
License
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
- I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
- I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
- I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
- I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
4. ________________
| We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |
